FDA Investigating Serious Risk of T-cell Malignancy
- Gaëlle Jamar
- Nov 30, 2023
- 1 min read
FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies
top of page
bottom of page